Abrocitinib

Janus Kinase Inhibitor — DERMATOLOGICALS

Key facts

Abrocitinib is an onp drug in the Janus Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the PMDA in 2021. Its mechanism of action is classified as Janus Kinase Inhibitors and P-Glycoprotein Inhibitors. DrugCentral lists 6 molecular targets, including JAK1, TYK2 and JAK3. Recorded indications include Atopic dermatitis.

• Approval status: onp (first approved 2021 by the PMDA).
• Drug class: Janus Kinase Inhibitor.
• Mechanism of action: Janus Kinase Inhibitors; P-Glycoprotein Inhibitors.
• Molecular targets: JAK1, TYK2, JAK3 and JAK2 (6 listed in DrugCentral).
• Indications: Atopic dermatitis.
• ATC code: D11AH08 (Agents for dermatitis, excluding corticosteroids).
• Molecular formula: C14H21N5O2S; molecular weight 323.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Atopic dermatitis

Mechanism & targets

• Mechanism of action (MoA): Janus Kinase Inhibitors; P-Glycoprotein Inhibitors
• Established pharmacologic class: Janus Kinase Inhibitor

Molecular targets (6)

Target	Gene	Action	Activity
Tyrosine-protein kinase JAK1	JAK1	inhibitor	IC50 7.54
Non-receptor tyrosine-protein kinase TYK2	TYK2	unknown	IC50 6.80
Tyrosine-protein kinase JAK3	JAK3	unknown	IC50 6.32
Tyrosine-protein kinase JAK2	JAK2	inhibitor	IC50 6.10
Vascular endothelial growth factor receptor 2	KDR	unknown	IC50 5.92
Amine oxidase [flavin-containing] A	MAOA	unknown	IC50 5.22

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-01-14	FDA	—	PFIZER Inc
2021-12-09	EMA	—	PFIZER EUROPE MA EEIG
2021-09-27	PMDA	—	PFIZER JAPAN INC.

ATC classification

ATC code	Therapeutic hierarchy
D11AH08	DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Agents for dermatitis, excluding corticosteroids

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: CYP2C19, CYP2C9 · No Clinical PGx
• FDA label: CYP2C19 · Actionable PGx
• HCSC label: CYP2C19, CYP2C9 · No Clinical PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Therapeutic product effect incomplete	332.9
Condition aggravated	316.7
Drug ineffective	312.5
Eczema herpeticum	252.9
Acne	162.9
Dermatitis atopic	158.3
Pruritus	118.5
Off label use	114.4
Lipids increased	108.9
Eczema	108.3
Therapeutic response unexpected	94.8
Cutaneous T-cell lymphoma	76.5

Chemical structure

• Molecular formula: C₁₄H₂₁N₅O₂S
• Molecular weight: 323.42 g/mol
• CAS number: 1622902-68-4
• InChIKey: IUEWXNHSKRWHDY-PHIMTYICNA-N
• PubChem CID: 78323835

CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)C1=NC=NC2=C1C=CN2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Abrocitinib used for?

DrugCentral lists the following indications for Abrocitinib: Atopic dermatitis.

How does Abrocitinib work?

Abrocitinib is classified as Janus Kinase Inhibitors and P-Glycoprotein Inhibitors; its molecular targets in DrugCentral include JAK1 (inhibitor), TYK2, JAK3 and JAK2 (inhibitor).

When was Abrocitinib first approved?

Abrocitinib was first approved by the PMDA in 2021.

What drug class does Abrocitinib belong to?

Abrocitinib is in the Janus Kinase Inhibitor class.

What is the chemical formula of Abrocitinib?

Abrocitinib has the molecular formula C14H21N5O2S and a molecular weight of 323.42 g/mol.

Sources

• DrugCentral drug card 5504 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3655081 — compound record and bioactivity
• PubChem CID 78323835 — chemical identifiers
• DrugBank DB14973 — drug record
• FDA UNII 73SM5SF3OR — substance identity
• DailyMed: FDA labels for Abrocitinib — current prescribing information (label search)
• UniProt P23458 (JAK1) — target protein
• UniProt P29597 (TYK2) — target protein
• UniProt P52333 (JAK3) — target protein
• UniProt O60674 (JAK2) — target protein
• UniProt P35968 (KDR) — target protein
• UniProt P21397 (MAOA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.